Human schistosomiasis: A living review of clinical and epidemiological concepts

Abstract

Schistosomiasis, as a neglected tropical disease, presents a public health challenge, particularly in impoverished tropical and subtropical areas. This living review focuses on the key aspects of schistosomiasis, including its etiology, epidemiology, pathophysiology, clinical features, diagnosis, prophylaxis, treatment, and control. We also examine the key aspects of schistosomiasis caused by Schistosoma mekongi, Schistosoma bovis, and Schistosoma curassoni. To date, praziquantel is the main drug for treating and reducing the transmission of schistosomiasis. The development of vaccines remains an important scientific goal in the control of this neglected disease.

Keywords

Schistosomiasis / Katayama fever

References

[1] Catalano S, Léger E, Fall CB, Borlase A, Diop SD, Berger D, et al. Multihost transmission of Schistosoma mansoni in Senegal, 2015-2018. Emerg Infect Dis 2020; 26(6): 1234-1242.

[2] Panzner U. Transmission modelling for human non-zoonotic schistosomiasis incorporating vaccination: Guiding decision-and policymaking. Parasitology 2024; 4(2): 101-128.

[3] World Health Organization. Ending the neglect to attain the Sustainable Development Goals: A road map for neglected tropical diseases 2021-2030. Geneva: World Health Organization; 2021.

[4] Deol AK, Fleming FM, Calvo-Urbano B, Walker M, Bucumi V, Gnandou I, et al. Schistosomiasis-assessing progress toward the 2020 and 2025 global goals. N Engl J Med 2019; 381(26): 2519-2528.

[5] Sarr M, Diop M, Bakhoum AJ, Doucoure S, Sow D, Bâ CT, et al. The Senegalese and Brazilian strains of Schistosoma mansoni exhibit high compatibility with Biomphalaria pfeifferi and Biomphalaria glabrata. Parasit Vectors 2025; 18(1): 314. doi: 10.1186/s13071-025-06918-5.

[6] Ministry of Health of Brazil. Health Surveillance Secretariat. Health surveillance guide: Single volume. 3rd ed. Brasília: Ministry of Health; 2024.

[7] Kittur N, King CH, Campbell CH, Kinung'hi S, Mwinzi PNM, Karanja DMS, et al. Persistent hotspots in schistosomiasis consortium for operational research and evaluation studies for gaining and sustaining control of schistosomiasis after four years of mass drug administration of praziquantel. Am J Trop Med Hyg 2019; 101(3): 617-627.

[8] Clerinx J, Soentjens P. Schistosomiasis: Epidemiology, clinical manifestations, and diagnosis. [Online]. Available from: https://www.uptodate.com/contents/schistosomiasis-epidemiology-clinical-manifestations-and-diagnosis. [Accessed on 6 September 2025].

[9] McManus DP, Dunne DW, Sacko M, Utzinger J, Vennervald BJ, Zhou XN. Schistosomiasis. Nat Rev Dis Primers 2018. doi: https://doi.org/10.1038/s41572-018-0013-8.

[10] Sayasone S, Khattignavong P, Keomalaphet S, Prasayasith P, Soundala P, Sannikone S, et al. Low prevalence of Schistosoma mekongi infection and high prevalence of other helminth infections among domestic animals in southern Lao People's Democratic Republic. Trop Med Infect Dis 2023; 8(7): 372. doi: 10.3390/tropicalmed8070372.

[11] Centers for Disease Control and Prevention (CDC). About schistosomiasis. 2024. [Online]. Available from: https://www.cdc.gov/schistosomiasis/about/index.html. [Accessed on 23 September 2024].

[12] Buonfrate D, Ferrari TCA, Adegnika AA, Stothard JR, Gobbi FG. Human schistosomiasis. Lancet 2025; 405(10479): 658-670.

[13] Barsoum RS, Esmat G, El-Baz T. Human schistosomiasis: Clinical perspective. J Adv Res 2013; 4(5): 433-444.

[14] Houlder EL, Costain AH, Nambuya I, Brown SL, Koopman JPR, Langenberg MCC, et al. Pulmonary inflammation promoted by type-2 dendritic cells is a feature of human and murine schistosomiasis. Nat Commun 2023; 14(1): 1863. doi: 10.1038/s41467-023-37502-z.

[15] Mickael CS, Graham BB. The role of type 2 inflammation in Schistosoma-induced pulmonary hypertension. Front Immunol 2019; 10: 27.

[16] Graham BB, Kumar R. Schistosomiasis and the pulmonary vasculature (2013 Grover Conference Series). Pulm Circ 2014; 4(3): 353-362.

[17] Casella ML, Fanni VSS, Verndl DO, Basso MC, Mello LF, Glina S. Schistosomiasis mansoni of the bladder simulating bladder cancer: A case report. Rev Soc Bras Med Trop 2009; 42(5): 581-582.

[18] De Liberato C, Berrilli F, Bossù T, Magliano A, Montalbano Di Filippo M, Di Cave D, et al. Outbreak of swimmer's itch in central Italy: Description, causative agent and preventive measures. Zoonoses Public Health 2019; 66(4): 377-381.

[19] Gray DJ, Ross AG, Li YS, McManus DP. Diagnosis and management of schistosomiasis. BMJ 2011; 342: d2651. doi: 10.1136/bmj.d2651.

[20] Langenberg MCC, Hoogerwerf MA, Janse JJ, van Lieshout L, Corstjens PLAM, Roestenberg M, et al. Katayama syndrome without Schistosoma mansoni eggs. Ann Intern Med 2019; 170(10): 732-733.

[21] Centers for Disease Control and Prevention (CDC). Clinical overview of schistosomiasis. 2024. [Online]. Available from: https://www.cdc.gov/schistosomiasis/hcp/clinical-overview/index.html#print. [Accessed on 25 November 2024].

[22] Pontes IBS, Duarte Neto AN, Dias CB. Glomerulopathy associated with schistosomiasis mansoni. Braz J Nephrol 2026; 48(1): e20250084. doi: 10.1590/2175-8239-JBN-2025-0084en.

[23] Bernardo TC. Insights on the pathophysiology of the progression to decompensated hepato-splenic schistosomiasis. Med Res Arch 2023;11(4). doi: 10.18103/mra.v11i4.3774.

[24] Veiga ZST, Fernandes FF, Guimarães L, Piedade J, Pereira GHS. Natural History of Hepatosplenic schistosomiasis (HSS) non-cirrhotic portal hypertension (NCPH): Influence of gastrointestinal bleeding and decompensation in prognosis. Trop Med Infect Dis 2023; 8(3): 145. doi: 10.3390/tropicalmed8030145.

[25] Ross AG, McManus DP, Farrar J, Hunstman RJ, Gray DJ, Li YS. Neuroschistosomiasis. J Neurol 2012; 259(1): 22-32.

[26] Carvalho OAM. Mansonic neuroschistosomiasis. Arq Neuro-Psiquiatr 2013; 71(9): 714-716.

[27] Kongs A, Marks G, Verle P, Van der Stuyft P. The unreliability of the Kato-Katz technique limits its usefulness for evaluating Schistosoma mansoni infections. Trop Med Int Health 2001; 6(3): 163-169.

[28] Soares FA, Benitez AN, Santos BM, Loiola SHN, Rosa SL, Nagata WB, et al. A historical review of the techniques of recovery of parasites for their detection in human stools. Rev Soc Bras Med Trop 2020; 53: e20190535.

[29] Keïta K, Loique Djeugoué S, Daoud Camara B, Alfousséni Doumbia A, OUmar Kamissoko C, Sandji O, et al. A cross-sectional analysis of schistosomiasis case detection by rectal mucosal biopsy among patients attending the digestive endoscopy unit of the internal medicine department. J Intervent Epidemiol Public Health 2025; 8(2): 1-24.

[30] Colley DG, Ramzy RM, Maganga J, Kinung'hi S, Odiere MR, Musuva RM, et al. The POC-CCA assay for detection of Schistosoma mansoni infection needs standardization in production and proper quality control to be reliable. Acta Trop 2023; 238: 106795. doi: 10.1016/j.actatropica.2022.106795.

[31] Hoekstra PT, De Dood CJ, Abdoel T, Hilt S, Van Diepen A, Polman K, et al. Detecting two Schistosoma circulating antigens-CCA and CAA-in urine and serum to improve diagnosis of human schistosomiasis. Front Parasitol 2024; 3: 1460331.

[32] Vaillant MT, Philippy F, Neven A, Barré J, Bulaev D, Olliaro PL, et al. Diagnostic tests for human Schistosoma mansoni and Schistosoma haematobium infection: A systematic review and meta-analysis. Lancet Microbe 2024; 5(4): e366-e378.

[33] Bansal A, Albano JE, Jayakumar D. Neuroschistosomiasis presenting as recurrent seizures: A case report. Surg Neurol Int 2025; 16: 51.

[34] Kamal I, Abdallah A, Khalid M, Musa A, Elzouki AN. Diagnosis of neuroschistosomiasis: How to overcome this challenge. Libyan J Med Sci 2020; 4(1): 35-37.

[35] Rissardo JP, Byroju VV, Caprara ALF. Neuroschistosomiasis: A narrative review of a multifaceted nature of a neglected tropical disease. 2024. [Online]. Available from: https://doi.org/10.20944/preprints202412.0822.v1.

[36] Thomas CM, Timson DJ. The mechanism of action of praziquantel: Six hypotheses. Curr Top Med Chem 2018; 18(18): 1575-1584.

[37] Abou-El-Naga IF, Amer EI, Boulos LM, El-Faham MH, Abou Seada NM, Younis SS. Biological and proteomic studies of Schistosoma mansoni with decreased sensitivity to praziquantel. Comp Immunol Microbiol Infect Dis 2019; 66: 101341. doi: 10.1016/j.cimid.2019.101341.

[38] Sanchez ME, Cupit PM, Bu L, Cunningham CE. Transcriptomic analysis of reduced sensitivity to praziquantel in Schistosoma mansoni. Mol Biochem Parasitol 2019; 228: 6-15.

[39] Afshar R, Daelken B, Greco B. PA-325 The pediatric praziquantel consortium: Our development journey to provide treatment to pre-school aged children. BMJ Glob Health 2023;8(Suppl_10). https://doi.org/10.1136/bmjgh-2023-EDC.162.

[40] Registro Brasileiro de Ensaios Clínicos. Assessment of praziquantel medication for children living in areas where schistosomiasis is common in Bahia and Sergipe. 2024. [Online]. Available from: https://ensaiosclinicos.gov.br/rg/RBR-86kcy37. [Accessed on 6 September 2025].

[41] The Pediatric Praziquantel Consortium. [Online]. Available from: https://www.pediatricpraziquantelconsortium.org/. [Accessed on 6 September 2025].

[42] Mengarda AC, Iles B, Rodrigues VC, Lima AL, Machado VP, Reatgui WS, et al. Praziquantel nanoparticle formulation for the treatment of schistosomiasis. ACS Appl Nano Mater 2025; 8(8): 3985-3997.

[43] Bustinduy AL, Edielu A, Ayebazibwe GK, Nakyesige R, Anguajibi V, Mpooya S, et al. Safety and efficacy of praziquantel 40 mg/kg versus 80 mg/kg in preschool-aged children with intestinal schistosomiasis in Uganda: A 2×2 factorial, double-blind, placebo-controlled, phase 2 randomised trial. Lancet Glob Health 2025; 13(6): e1091-e1100.

[44] El-Kassas M, El Sheemy R, Elbadry M. Strategies and achievements in controlling and eliminating schistosomiasis from Egypt. Egypt Liver J 2024;14(31). doi: org/10.1186/s43066-024-00339-2.

[45] World Health Organization. WHO guideline on control and elimination of human schistosomiasis. Geneva: World Health Organization; 2022.

[46] Mendonça AF, Jansen ACS, da Cruz Pinheiro I, de Almeida DTL, do Ano JDA, Bezerra JMT, et al. Impacts of educational interventions on schistosomiasis awareness in a school community. J Trop Pathol 2025; 54(1): 1-13.

[47] Mertelsmann AM, Bowers SF, Wright D, Maganga JK, Mazigo HD, Ndhlovu LC, et al. Effects of Schistosoma haematobium infection and treatment on the systemic and mucosal immune phenotype, gene expression and microbiome: A systematic review. PLoS Negl Trop Dis 2024; 18(9): e0012456. doi: 10.1371/journal.pntd.0012456

[48] Pennance T, Ame SM, Amour AK, Suleiman KR, Muhsin MA, Kabole F, et al. Transmission and diversity of Schistosoma haematobium and S. bovis and their freshwater intermediate snail hosts Bulinus globosus and B. nasutus in the Zanzibar Archipelago, United Republic of Tanzania. PLoS Negl Trop Dis 2022; 16(7): e0010585.

[49] Gryseels B, Polman K, Clerinx J, Kestens L. Human schistosomiasis. Lancet 2006; 368(9541): 1106-1118.

[50] Silva R, Thiengo R, Conceição MJ, Rey L, Filho EP, Ribeiro PC. Cystoscopy in the diagnosis and follow-up of urinary schistosomiasis in Brazilian soldiers returning from Mozambique, Africa. Rev Inst Med Trop Sao Paulo 2006; 48(1): 39-42.

[51] Lackey EK, Horrall S. Schistosomiasis. 2023. [Online]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK554434/. [Accessed on 7 November 2025].

[52] Steinmann P, Keiser J, Bos R, Tanner M, Utzinger J. Schistosomiasis and water resources development: Systematic review, meta-analysis, and estimates of people at risk. Lancet Infect Dis 2006; 6(7): 411-425.

[53] Cleland CR, Tukahebwa EM, Fenwick A, Blair L. Mass drug administration with praziquantel reduces the prevalence of Schistosoma mansoni and improves liver morbidity in untreated preschool children. Trans R Soc Trop Med Hyg 2014; 108(9): 575-581.

[54] Riveau G, Schacht AM, Dompnier JP, Deplanque D, Seck M, Waucquier N, et al. Safety and efficacy of the rSh28GST urinary schistosomiasis vaccine: A phase 3 randomized, controlled trial in Senegalese children. PLoS Negl Trop Dis 2018; 12(12): e0006968.

[55] Tebeje BM, Harvie M, You H, Rivera V, McManus DP. T cell-mediated immunity in CBA mice during Schistosoma japonicum infection. Exp Parasitol 2019; 204: 107725.

[56] Stothard JR, Sousa-Figueiredo JC, Betson M, Bustinduy A, Reinhard-Rupp J. Schistosomiasis in African infants and preschool children: Let them now be treated. Trends Parasitol 2013; 29(4): 197-205.

[57] Gordon CA, Kurscheid J, Williams GM, Clements ACA, Li Y, Zhou XN, et al. Asian schistosomiasis: Current status and prospects for control leading to elimination. Trop Med Infect Dis 2019; 4(1): 40.

[58] Wang LD, Chen HG, Guo JG, Zeng XJ, Hong XL, Xiong JJ, et al. A strategy to control transmission of Schistosoma japonicum in China. N Engl J Med 2009; 360(2): 121-128.

[59] Vellere I, Mangano VD, Cagno MC, Gobbi F, Ragusa A, Bartoloni A, et al. Imported human Schistosoma japonicum: A report on two cases in Filipino migrants present in Italy and a systematic review of literature. Travel Med Infect Dis 2020; 36: 101496.

[60] Baptista-Fernandes T, Pessanha M, Cabral P, Relvas L, Marques T. Myeloradiculopathy by Schistosoma intercalatum: An underdiagnosed disease. A clinical case 2013. [Online]. Available from: https://elibrary.escmid.org/?search%5Border%5D=relevance&search%5Bpage%5D=1&search%5Bquery%5D=%22P.%20Cabral%22. [Accessed on 6 September 2025].

[61] Kołodziej P, Szostakowska B, Lass A, Sulima M, Sikorska K, Kocki J, et al. Chronic intestinal schistosomiasis caused by co-infection with Schistosoma intercalatum and Schistosoma mansoni. Lancet Infect Dis 2024; 24(3): e196-e205.

[62] Agniwo P, Dembélé L, Koné A, Sidibé B, Konaté A, Garango A, et al. Evaluation of praziquantel efficacy in children after two decades of mass distribution in Bamako, Mali. J Interv Epidemiol Public Health 2025; 8(4): 92.

[63] Khieu V, Sayasone S, Muth S, Kirinoki M, Laymanivong S, Ohmae H, et al. Elimination of schistosomiasis mekongi from endemic areas in Cambodia and the Lao People's Democratic Republic: Current status and plans. Trop Med Infect Dis 2019; 4(1): 30.

[64] Uthailak N, Adisakwattana P, Thiangtrongjit T, Limpanont Y, Chusongsang S, Chusongsang Y, et al. Discovery of Schistosoma mekongi circulating proteins and antigens in infected mouse sera. PLoS One 2022; 17(10): e0275992.

[65] Kumagai T, Matsumoto-Takahashi ELA, Ishikawa H, Keomalaphet S, Khattignavong P, Soundala P, et al. Detection of Schistosoma mekongi DNA in human stool and intermediate host snail Neotricula aperta via loop-mediated isothermal amplification assay in Lao PDR. Pathogens 2022; 11(12): 1413.

[66] Attwood SW, Liu L, Huo GN. Population genetic structure and geographical variation in Neotricula aperta (Gastropoda: Pomatiopsidae), the snail intermediate host of Schistosoma mekongi (Digenea: Schistosomatidae). PLoS Negl Trop Dis 2019; 13(1): e0007061.

[67] Younis SS, Abou-El-Naga IF, Radwan KH. Molluscicidal effect of green synthesized silver nanoparticles using Azadirachta indica on Biomphalaria alexandrina snails and Schistosoma mansoni cercariae. Asian Pac J Trop Biomed 2023; 13(1): 35-44.

[68] Zhou M, Xu L, Xu D, Chen W, Khan J, Hu Y, et al. Chromosome-scale genome of the human blood fluke Schistosoma mekongi and its implications for public health. Infect Dis Poverty 2023; 12(1): 104.

[69] Centers for Disease Control and Prevention (CDC). Clinical care of schistosomiasis. [Online]. Available from: https://www.cdc.gov/schistosomiasis/hcp/treatment/index.html. [Accessed on 25 November 2025].

[70] Webster BL, Southgate VR, Littlewood DT. A revision of the interrelationships of Schistosoma including the recently described Schistosoma guineensis. Int J Parasitol 2006; 36(8): 947-955.

[71] Sene-Wade M, Marchand B, Rollinson D, Webster BL. Urogenital schistosomiasis and hybridization between Schistosoma haematobium and Schistosoma bovis in adults living in Richard-Toll, Senegal. Parasitology 2018; 145(13): 1723-1726.

[72] Angora EK, Allienne JF, Rey O, Menan H, Touré AO, Coulibaly JT, et al. High prevalence of Schistosoma haematobium × Schistosoma bovis hybrids in schoolchildren in Côte d'Ivoire. Parasitology 2019; 147(3): 287-294.

[73] Teukeng FFD, Blin M, Bech N, Gomez MR, Zein-Eddine R, Simo AMK, et al. Hybridization increases genetic diversity in Schistosoma haematobium populations infecting humans in Cameroon. Infect Dis Poverty 2022; 11(1): 30.

[74] Léger E, Garba A, Hamidou AA, Webster BL, Pennance T, Rollinson D, et al. Introgressed animal schistosomes Schistosoma curassoni and S. bovis naturally infecting humans. Emerg Infect Dis 2016; 22(12): 2212-2214.

[75] Ekloh W, Asafu-Adjaye A, Tawiah-Mensah CNL, Ayivi-Tosuh SM, Quartey NK, Aiduenu AF, et al. A comprehensive exploration of schistosomiasis: Global impact, molecular characterization, drug discovery, artificial intelligence and future prospects. Heliyon 2024; 10(12): e33070.